Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Boyle, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boyle, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:16-18, 2002
© 2002 European Society for Medical Oncology

Editorial

Faecal occult blood testing (FOBT) as screening for colorectal cancer: the current controversy

P. Boyle

Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy

Colorectal cancer is the fourth most common form of cancer that occurs worldwide, with an estimated 782 900 new cases diagnosed in 1990 [1]. The disease is not uniformly fatal, although there are large differences in survival according to the stage at which the disease is detected. In advanced colorectal cancer in which curative resection is possible, 5-year survival in Dukes’ B is 45%, dropping to 30% in Dukes’ C [2]. Five year survival in resected Dukes’ A is ~80% and survival following simple resection of an adenomatous pedunculated polyp containing carcinoma in situ (or severe dysplasia) or intramucosal carcinoma is generally close to 100%. Although it has been argued that death from colorectal cancer may be avoidable [3], it is estimated that there are still 394 000 deaths from colorectal cancer annually worldwide [4].

The identification of a well-defined pre-malignant lesion, . . . [Full Text of this Article]

Acknowledgements

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
P. Boyle, H. Vainio, R. Smith, R. Benamouzig, W. C. Lee, N. Segnan, K. Takima, and Y. Tsubono
Workgroup I: criteria for screening. UICC International Workshop on Facilitating Screening for Colorectal Cancer, Oslo, Norway (29 and 30 June 2002)
Ann. Onc., January 1, 2005; 16(1): 25 - 30.
[Full Text] [PDF]

Home page
 Ann OncolHome page
G. Castiglione and M. Zappa
Debate on colorectal cancer screening by faecal occult blood
Ann. Onc., February 1, 2003; 14(2): 342 - 344.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
P. Boyle
Screening
Eur. Respir. J., January 1, 2003; 21(39_suppl): 3S - 15s.
[Abstract] [Full Text] [PDF]